Blog for Masters & MBAs | EADA
  • The EADA Experience
  • Alumni Stories
  • Life in Barcelona
  • Admissions & Financing
No Result
View All Result
Blog for Masters & MBAs | EADA
  • The EADA Experience
  • Alumni Stories
  • Life in Barcelona
  • Admissions & Financing
No Result
View All Result
Masters & MBAs | EADA
No Result
View All Result

Programme Director, Dr Anton-Giulio Manganelli, talks to us about Covid-19 and the Pharma & Biotech Industry

March 26, 2020
in The EADA Experience
0 0
Home The EADA Experience
Share on FacebookShare on TwitterShare on LinkedIn

We spoke to Programme Director of the Master in Pharma & Biotech Management, Dr Anton-Giulio Manganelli, to get his take on the impact of Covid-19 on the Biotech industry. 

Dr Manganelli holds a Phd in Economics from Toulouse School of Economics and a Master from Bocconi University, and has extensive work experience in research and consultancy on competition and health economics.

Dr Anton-Giulio Manganelli, Programme Director for the Master in Pharma & Biotech Management

How are pharma and biotech companies facing the challenge of the COVID-19 outbreak?

The COVID-19 outbreak has been a shock for the industry. It started a race to find a vaccine and to develop diagnostic toolkits. Several companies have already successfully developed the diagnostic toolkit, which regulators approved exceptionally quickly, but it will take longer before a vaccine is on the market. This is due to regulations: while it is technically feasible to find a potential vaccine relatively quickly (many companies claim to have already found it), an optimistic prevision of the time required to run proper clinical trials is 12-18 months.

With this in mind, we can identify 3 clear challenges that companies in the sector are facing:

  • Meeting the ever-growing demand for diagnostic kits
  • Researching and identifying a potential vaccine
  • Organising clinical trials for potential vaccines

On a more basic level, companies are struggling to ensure that they can still function effectively and efficiently under the current circumstances. COVD-19 has seen a significant –and sudden– increase in employees working remotely, and the supply chain of many pharma and biotech companies has been disrupted by the closure of manufacturing plants around the world. Many companies, especially those producing generic drugs, rely on Chinese and Indian manufacturers for their active principles, and COVID-19 has put those supplies at risk.

Can you tell us a bit about digital health and how it relates to COVID-19?

Virtually all pharma and biotech companies are facing the challenge of switching to digital health, and COVID-19 has been an extraordinary push in that direction.  

In some countries in Europe there is a debate about how to use apps that track people that were in contact with sick people in order to reduce the spread of the disease – these apps were already used in South Korea. Moreover, any diagnostic app may make the identification of sick people easier and, at the same, make sure that doctors do not get infected by the patient. This highlights the increasingly important intersection between the traditional pharmaceutical & biotech management and the new trends such as digital health.

How is the health crisis affecting the industry financially?

COVID-19 has dramatically affected the majority of the sectors. There are clear risks for pharma and biotech sectors, some of which I have already mentioned. First, the supply chain disruption for companies that rely on Chinese and Indian manufacturers has been notable. Although companies have already reduced their dependency on these suppliers, changing supplier comes at a cost.

Second, there is a fear that productivity will decrease for employees working remotely. For example, the work of pharma representatives is traditionally conducted primarily through in-person meetings with doctors, and working remotely obliges representatives to find new (possibly less effective) ways to connect with doctors.

Third, a considerable risk for companies researching vaccines and conducting clinical trials is that the investment in R&D does not always have a positive return. In the current COVID-19 environment, the line between a dramatic success and a terrible failure becomes much thinner (e.g., being the first or the second company with the vaccine can make a huge difference in the company’s profits). Even for companies that initially find a relatively effective vaccine, this vaccine is always at risk of being replaced by a more effective one further down the line.

The efforts to find the sequence of the genome of COVID-19 have been exceptional

How are pharma and biotech companies helping in the battle against COVID-19?

The efforts to find the sequence of the genome of COVID-19 have been exceptional – just a few weeks into the epidemic, we already had the full genome of the virus. Artificial intelligence has also been crucial in explaining the relationship between the sequence changes in COVID-19 and the development of the epidemic.

In terms of finding a vaccine, some companies claim that they have already found one, although any new medication must undergo a rigorous testing phase lasting 12 to 18 months.

What skills does a manager need to be able to deal with challenges like this one?

Managers in the pharma and biotech fields need flexibility, creativity and resilience. Flexibility and creativity because they need to find alternative ways of working: working remotely can be challenging, and this is especially true when managing a team to align efforts. Resilience because pharma and biotech companies are, and will continue to be, under a lot of pressure from governments and shareholders alike to find a solution to the epidemic.

Related

Tags: From our facultyInnovationMaster in Pharma & Biotech ManagementTechnology
ShareTweetShare
Previous Post

Meet Veronika Bitter, Vice President of the Consulting Club 2019-2020

Next Post

How long will the 2020 Economic Crisis last? Speed does not Mean Precipitation.

Related Posts

First Winner SAP Scholarship for Women in Business, Noor Spieringhs
The EADA Experience

January Intake Winner of the SAP Scholarship for Women in Business, Madalena Chaves

May 19, 2022

...

EADA’s Company Connection Week
The EADA Experience

EADA’s Company Connection Week

May 9, 2022

...

Next Post
How long will the 2020 Economic Crisis last? Speed does not Mean Precipitation.

How long will the 2020 Economic Crisis last? Speed does not Mean Precipitation.

Languages

  • enEnglish

Tags

CFA Institute EADA Careers Entrepreneurship & startups Events Exchange programme From our faculty Innovation International business trips International Masters International MBA Leadership LeadTech Global Executive MBA Master in Digital Business (DMBA ISDI-Leadership EADA) Master in Finance Master in FinTech & Business Analytics Master in Management Master in Marketing Master in Pharma & Biotech Management Master in Sustainable Business & Innovation Master in Tourism & Hospitality Management Scholarships Sustainability Technology
  • The EADA Experience
  • Alumni Stories
  • Life in Barcelona
  • Admissions & Financing

© 2022 EADA Business School.

No Result
View All Result
  • The EADA Experience
  • Alumni Stories
  • Life in Barcelona
  • Admissions & Financing

© 2022 EADA Business School.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In